消癌平胶囊联合顺铂和替加氟治疗晚期食管癌的临床研究

目的探讨消癌平胶囊联合顺铂和替加氟注射液治疗食管癌的临床疗效。方法选取2016年4月—2018年4月在重庆市开州区人民医院治疗的食管癌患者86例,根据用药方案的差别分为对照组(43例)和治疗组(43例)。对照组静脉滴注顺铂注射液,80 mg/m~2,1次/d,连续3周,休息1周,每4周为1个周期,同时静脉滴注替加氟注射液,15～20 mg/kg溶于生理盐水500 mL中,1次/d。治疗组在对照组基础上口服消癌平胶囊,4粒/次,3次/d。两组患者均治疗3个周期。观察两组患者临床疗效,同时比较治疗前后两组患者癌胚抗原(CEA)、鳞状上皮细胞癌抗原(SCC-Ag)、细胞角蛋白19的可溶性片段(CYFRA21-1)、糖抗原199(CA199)、血管内皮生长因子(VEGF)、基质金属蛋白酶-9(MMP-9)、骨桥蛋白(OPN)、可溶性白细胞介素-2受体(s IL-2R)及QLQ-C30和KPS评分。结果治疗后,对照组客观缓解率和临床获益率分别为41.86%、72.09%,均分别显著低于治疗组的69.77%、86.05%,两组比较差异均具有统计学意义(P0.05)。治疗后,两组患者血清CEA、SCC-Ag、CYFRA21-1、CA199、VEGF、MMP-9、OPN、sIL-2R水平均显著降低(P0.05),且治疗组患者这些因子水平明显低于对照组(P0.05)。治疗后,两组QLQ-C30量表和KPS评分均明显升高(P0.05),且治疗组患者QLQ-C30和KPS评分明显高于对照组(P0.05)。结论消癌平胶囊联合顺铂与替加氟治疗食管癌可有效改善患者症状,降低机体肿瘤标志物水平和侵袭细胞因子水平,有利于提高患者生活质量。

Clinical study on Xiaoaiping Capsules combined with cisplatin and tegafur in treatment of esophageal cancer

Objective To investigate the clinical efficacy of Xiaoaiping Capsules combined with cisplatin and tegafur in treatment of esophageal cancer. Methods Patients (86 cases) with esophageal cancer in Kaizhou District People''s Hospital of Chongqing from April 2016 to April 2018 were divided into control (43 cases) and treatment (43 cases) groups based on different treatments. Patients in the control group were iv administered with Cisplatin Injection, 80 mg/m², and at the same time they were iv administered with Tegafur Injection, 15-20 mg/kg added into 500 mL normal saline, once daily, continuous treatment for 3 weeks, then withdraw 1 week, repeated every four weeks. Patients in the treatment group were po administered with Xiaoaiping Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 3 treatment cycles. After treatment, the clinical efficacy was evaluated, and the CEA, SCC-Ag, CYFRA21-1, CA199, VEGF, MMP-9, OPN, and sIL-2R levels, QLQ-C30, and KPS scores in two groups before and after treatment were compared. Results After treatment, the objective reaction rate and clinical benefit rate in the control group were 41.86% and 72.09%, which were significantly lower than 69.77% and 86.05% in the treatment group, respectively, and there were differences between two groups (P<0.05). After treatment, the CEA, SCC-Ag, CYFRA21-1, CA199, VEGF, MMP-9, OPN, and sIL-2R levels in two groups were significantly decreased (P<0.05), and these factors levels in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the QLQ-C30 and KPS scores in two groups were significantly increased (P<0.05), and which in the treatment group were significantly higher than those in the control group (P<0.05). Conclusion Xiaoaiping Capsules combined with cisplatin and tegafur in treatment of esophageal cancer can effectively improve the clinical symptoms, reduce the level of tumor markers and invasive cytokines, and improve the quality of life.